Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/20/25
End: 03/29/26
Due: 03/29/27
Phase: N/A
Priority: Normal
Start: 11/09/20
End: 04/26/22
Due: 04/26/23
Phase: N/A
Priority: Normal
Start: 06/07/22
End: 06/04/24
Due: 06/04/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants. | NCT07016464 | reMYND | user2@example.com | None | 2025-03-20 | 2026-03-29 | 2027-03-29 | - | - | 2025-07-14 |
| A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127 | NCT04672135 | reMYND | user2@example.com | None | 2020-11-09 | 2022-04-26 | 2023-04-26 | - | - | 2025-07-14 |
| A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease | NCT05478031 | reMYND | user2@example.com | None | 2022-06-07 | 2024-06-04 | 2025-06-04 | - | - | 2025-07-14 |